These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 15095753)

  • 1. The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure.
    Cardiovasc J S Afr; 2004; 15(1):42-3. PubMed ID: 15095753
    [No Abstract]   [Full Text] [Related]  

  • 2. CHARM study in CHF patients with impaired LV function reinforces benefits of candesartan cilexetil (Atacand).
    Cardiovasc J S Afr; 2004; 15(5):252. PubMed ID: 15483738
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H; Komuro I
    Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring new treatment strategies in heart failure.
    Swedberg K
    Blood Press Suppl; 2000; 1():44-8. PubMed ID: 11059637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    McKelvie RS
    J Hypertens Suppl; 2006 Mar; 24(1):S9-13. PubMed ID: 16601580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
    Plosker GL; Keam SJ
    Pharmacoeconomics; 2006; 24(12):1249-72. PubMed ID: 17129078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHARM shows improvement in NYHA functional class with candesartan.
    Cardiovasc J S Afr; 2004; 15(2):96-7. PubMed ID: 15148548
    [No Abstract]   [Full Text] [Related]  

  • 9. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
    Rakugi H; Ogihara T
    Nihon Rinsho; 2001 Oct; 59(10):2051-61. PubMed ID: 11676153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial.
    Bhakta S; Dunlap ME
    Cleve Clin J Med; 2004 Aug; 71(8):665-73. PubMed ID: 15449762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.
    Swedberg K; Pfeffer M; Granger C; Held P; McMurray J; Ohlin G; Olofsson B; Ostergren J; Yusuf S
    J Card Fail; 1999 Sep; 5(3):276-82. PubMed ID: 10496201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
    Swedberg K; McMurray JJ
    Eur Heart J; 2004 Mar; 25(5):357-8. PubMed ID: 15033244
    [No Abstract]   [Full Text] [Related]  

  • 14. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P; Reismann J; Pohlmeyer H; Düsing R
    Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candesartan cilexetil: an update.
    Joost A; Schunkert H; Radke PW
    Expert Opin Pharmacother; 2011 Aug; 12(11):1769-80. PubMed ID: 21651457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
    Franke H
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010
    [No Abstract]   [Full Text] [Related]  

  • 17. Candesartan and heart failure: the allure of CHARM.
    White HD
    Lancet; 2003 Sep; 362(9386):754-5. PubMed ID: 13678864
    [No Abstract]   [Full Text] [Related]  

  • 18. [CHARM].
    Momomura S
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():431-6. PubMed ID: 16981575
    [No Abstract]   [Full Text] [Related]  

  • 19. The CHARM programme.
    Penston J
    Lancet; 2003 Nov; 362(9396):1678; author reply 1678-9. PubMed ID: 14630459
    [No Abstract]   [Full Text] [Related]  

  • 20. The CHARM programme.
    Mansour J; Peltier M; Oprisiu R; Achard JM; Fournier A
    Lancet; 2003 Nov; 362(9396):1676-7; author reply 1678-9. PubMed ID: 14630455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.